Corrigendum to 'Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study' Cancer Genetics 270-271 (2022) 32-38.

The authors regret < the actual time for all the medical records we reviewed was August 2021. We mistook the time for when the time patients was diagnosed with lung cancer.>. The authors would like to apologise for any inconvenience caused. Molecular determinants of clinical outcomes for anaplastic lymphoma kinase–positive non-small cell lung cancer in Chinese patients: A retrospective studyCancer GeneticsVol. 270-271PreviewAnaplastic lymphoma kinase (ALK) rearrangement is a unique molecular subtype of non-small cell lung cancer (NSCLC) that was first discovered in 2007 [1]. Most patients with this rearrangement that are diagnosed with adenocarcinoma are, on average, 10 years younger than patients with mutated EGFR and have never smoked or had a light smoking history [2]. ALK tyrosine kinase inhibitors (TKIs) are associated with a substantial improvement in patient survival and have been used as the first-line treatment [3]. Full-Text PDF Open Access